Vivus
FDA panel backs liraglutide for obesity
September 12, 2014Manufacturing and Production, Sales and Marketing Arena Pharmaceuticals, Belviq, Novo Nordisk, Qsymia, Victoza, Vivus, diabetes, obesity
An FDA panel has voted 14-1 to allow a form of Novo Nordisk’s type 2 diabetes treatment Victoza to help …
Doctor questions FDA’s diet drug approvals
August 23, 2013Research and Development, Sales and Marketing BMJ, Belviq, EMA, FDA, Vivus, diet pills, obesity
FDA approves new erectile dysfunction drug
April 30, 2012Sales and Marketing ED, FDA, Stendra. Pfizer, Vivus, viagra
The FDA has approved Vivus’ erectile dysfunction drug Stendra, and the firm hopes its rapid mode of action will help …
Obesity drug supported by FDA panel
February 23, 2012Sales and Marketing FDA, Qnexa, Vivus, Xenical, obesity
Vivus’ obesity drug Qnexa has been supported by an FDA panel, two years after it was knocked back by the …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
September 25, 2026
One in three UK women with migraine say symptoms taken less seriously
September 24, 2026
Report highlights scope to expand day surgery
September 23, 2026
Sygnature formalises drug discovery collaboration with X-Chem
September 22, 2026
Codis appoints Steven Facer as chief commercial officer
September 21, 2026
